Theralase Technologies Inc. (CVE:TLT – Get Free Report) shares traded up 24.5% on Monday . The company traded as high as C$0.36 and last traded at C$0.31. 645,781 shares traded hands during mid-day trading, an increase of 58% from the average session volume of 407,451 shares. The stock had previously closed at C$0.25.
Theralase Technologies Stock Performance
The stock has a market cap of C$70.20 million, a PE ratio of -14.72 and a beta of -0.35. The company has a debt-to-equity ratio of 14.85, a current ratio of 1.91 and a quick ratio of 3.40. The stock has a 50-day simple moving average of C$0.18 and a 200-day simple moving average of C$0.19.
About Theralase Technologies
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Read More
- Five stocks we like better than Theralase Technologies
- Do not delete, read immediately
- How a Family Trust May Be Able To Help Preserve Your Wealth
- The Crash Has Already Started (Most Just Don’t See It Yet)
- Stop buying the dip (Do this instead)
- NEW LAW: Congress Approves Setup For Digital Dollar?
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
